Literature DB >> 15063786

Local delivery of E2F decoy oligodeoxynucleotides using ultrasound with microbubble agent (Optison) inhibits intimal hyperplasia after balloon injury in rat carotid artery model.

Naotaka Hashiya1, Motokuni Aoki, Katsuro Tachibana, Yoshiaki Taniyama, Keita Yamasaki, Kazuya Hiraoka, Hirofumi Makino, Kaneda Yasufumi, Toshio Ogihara, Ryuichi Morishita.   

Abstract

Since restenosis after angioplasty still remains a major clinical problems, inhibition of neointimal formation is an important subject. In this study, we focused on the transcription factor, E2F, that plays a pivotal role in the transactivation of cell-cycle regulatory genes, and also we developed a newly delivery system of decoy oligodeoxynucleotides (ODN). We transfected E2F decoy ODN mixed with an echo-contrast microbubble agent (Optison) into rat carotid artery balloon-injured model by using therapeutic ultrasound (US) to inhibit neointimal formation. Two weeks after transfection, the intimal to medial area ratio in E2F decoy+Optison+US group was significantly decreased (P < 0.01). Inhibition of cell growth was also confirmed by PCNA staining. No apparent toxicity such as inflammation could be detected in blood vessels transfected with E2F decoy ODN with Optison and ultrasound. Overall, the present studies demonstrated a novel non-viral ODN transfer method into blood vessels. A novel therapeutic strategy using E2F decoy ODN with Optison using ultrasound may be useful to inhibit restenosis in clinical practice without a viral vector.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15063786     DOI: 10.1016/j.bbrc.2004.03.070

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  16 in total

1.  Calreticulin Regulates Neointima Formation and Collagen Deposition following Carotid Artery Ligation.

Authors:  Kurt A Zimmerman; Dongqi Xing; Manuel A Pallero; Ailing Lu; Masahito Ikawa; Leland Black; Kenneth L Hoyt; Janusz H Kabarowski; Marek Michalak; Joanne E Murphy-Ullrich
Journal:  J Vasc Res       Date:  2016-02-25       Impact factor: 1.934

Review 2.  Cardiovascular therapeutic uses of targeted ultrasound contrast agents.

Authors:  Susan T Laing; David D McPherson
Journal:  Cardiovasc Res       Date:  2009-07-06       Impact factor: 10.787

Review 3.  Microbubbles in ultrasound-triggered drug and gene delivery.

Authors:  Sophie Hernot; Alexander L Klibanov
Journal:  Adv Drug Deliv Rev       Date:  2008-04-03       Impact factor: 15.470

4.  Focused in vivo delivery of plasmid DNA to the porcine vascular wall via intravascular ultrasound destruction of microbubbles.

Authors:  Linsey C Phillips; Alexander L Klibanov; Douglas K Bowles; Michael Ragosta; John A Hossack; Brian R Wamhoff
Journal:  J Vasc Res       Date:  2009-11-18       Impact factor: 1.934

5.  Key factors that affect sonoporation efficiency in in vitro settings: the importance of standing wave in sonoporation.

Authors:  Manabu Kinoshita; Kullervo Hynynen
Journal:  Biochem Biophys Res Commun       Date:  2007-05-30       Impact factor: 3.575

Review 6.  Cardiovascular gene delivery: The good road is awaiting.

Authors:  L P Brewster; E M Brey; H P Greisler
Journal:  Adv Drug Deliv Rev       Date:  2006-07-07       Impact factor: 15.470

Review 7.  Physically facilitating drug-delivery systems.

Authors:  Jorge I Rodriguez-Devora; Sunny Ambure; Zhi-Dong Shi; Yuyu Yuan; Wei Sun; Tao Xui
Journal:  Ther Deliv       Date:  2012-01

8.  Ultrasonically targeted delivery into endothelial and smooth muscle cells in ex vivo arteries.

Authors:  Daniel M Hallow; Anuj D Mahajan; Mark R Prausnitz
Journal:  J Control Release       Date:  2007-01-12       Impact factor: 9.776

Review 9.  Neointimal hyperplasia associated with synthetic hemodialysis grafts.

Authors:  Li Li; Christi M Terry; Yan-Ting E Shiu; Alfred K Cheung
Journal:  Kidney Int       Date:  2008-07-30       Impact factor: 10.612

Review 10.  Ultrasound mediated delivery of drugs and genes to solid tumors.

Authors:  Victor Frenkel
Journal:  Adv Drug Deliv Rev       Date:  2008-04-03       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.